Skip to content

Author

Xiao-Wei Wu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP.

Acute myeloid leukemia (AML) is prone to relapse driven by therapy-persistent residual cells. To discover specific vulnerabilities in this population, we performed genome-wide CRISPR interference screens in leukemia cells treated with multiple agents. KHSRP was the top hit, whose depletion sensitized AML cells to thera...

Qing-Yu Luo, Karley S. Whalen, Xiao-Wei Wu et al. · 0 citations
Open access Sep 2026

Cyclin E-CDK2 regulates cancer cell transcriptional program and response to immunotherapy through BRD4.

The cyclin E-cyclin-dependent kinase 2 (CDK2) complex is a component of mammalian cell-cycle machinery that drives cell division. Hyperactivation of cyclin E-CDK2 is frequent in human cancers. Small-molecule CDK2 inhibitors are tested in clinical trials for cancer patients. Here, we report that cyclin E-CDK2 has a cell...

Chen Chu, Shanshan Zheng, Ning Mitchell et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.